Paromomycin sulfate warnings and precautions: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) m (→Precautions) |
||
| Line 6: | Line 6: | ||
The use of this antibiotic, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. Constant observation of the patient is essential. If new infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken. | The use of this antibiotic, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. Constant observation of the patient is essential. If new infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken. | ||
The drug should be used with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption. | The drug should be used with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption. | ||
This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PAROMOMYCIN SULFATE CAPSULE [CARACO PHARMACEUTICAL LABORATORIES, LTD.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22494bde-a53e-4b3c-a89b-0ccda341f28f | publisher = | date = | accessdate = }}</ref> | This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have [[aspirin]] [[hypersensitivity]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = PAROMOMYCIN SULFATE CAPSULE [CARACO PHARMACEUTICAL LABORATORIES, LTD.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=22494bde-a53e-4b3c-a89b-0ccda341f28f | publisher = | date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
Revision as of 00:47, 31 December 2013
| Paromomycin Sulfate |
|---|
| PAROMOMYCIN SULFATE capsule® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Dosage and Administration |
| How Supplied |
| Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Precautions
The use of this antibiotic, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. Constant observation of the patient is essential. If new infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken. The drug should be used with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption. This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.[1]
References
Adapted from the FDA Package Insert.